Columbus Circle Investors Trims Position in Alexion Pharmaceuticals (ALXN)

Columbus Circle Investors cut its position in shares of Alexion Pharmaceuticals (NASDAQ:ALXN) by 18.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 188,836 shares of the biopharmaceutical company’s stock after selling 42,966 shares during the quarter. Columbus Circle Investors owned 0.08% of Alexion Pharmaceuticals worth $21,048,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. TIAA CREF Investment Management LLC raised its holdings in Alexion Pharmaceuticals by 12.1% during the fourth quarter. TIAA CREF Investment Management LLC now owns 3,836,919 shares of the biopharmaceutical company’s stock worth $458,857,000 after purchasing an additional 414,969 shares during the last quarter. Clearbridge Investments LLC raised its holdings in shares of Alexion Pharmaceuticals by 9.5% in the fourth quarter. Clearbridge Investments LLC now owns 3,541,871 shares of the biopharmaceutical company’s stock worth $423,572,000 after acquiring an additional 307,117 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Alexion Pharmaceuticals by 10.4% in the fourth quarter. Franklin Resources Inc. now owns 2,583,710 shares of the biopharmaceutical company’s stock worth $308,986,000 after acquiring an additional 243,650 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 2.8% in the fourth quarter. Geode Capital Management LLC now owns 2,256,415 shares of the biopharmaceutical company’s stock worth $269,251,000 after acquiring an additional 62,266 shares during the last quarter. Finally, UBS Asset Management Americas Inc. raised its holdings in shares of Alexion Pharmaceuticals by 10.3% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock worth $223,818,000 after acquiring an additional 174,606 shares during the last quarter. 95.67% of the stock is owned by hedge funds and other institutional investors.

In other news, Director Christopher J. Coughlin purchased 10,000 shares of the stock in a transaction on Monday, April 30th. The stock was purchased at an average price of $120.79 per share, with a total value of $1,207,900.00. Following the completion of the transaction, the director now owns 26,333 shares in the company, valued at $3,180,763.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Heidi L. Wagner sold 698 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $119.35, for a total value of $83,306.30. The disclosure for this sale can be found here. 4.35% of the stock is owned by insiders.

Shares of NASDAQ:ALXN opened at $121.15 on Friday. The firm has a market capitalization of $26.92 billion, a PE ratio of 22.41, a price-to-earnings-growth ratio of 1.09 and a beta of 1.11. The company has a quick ratio of 2.86, a current ratio of 3.35 and a debt-to-equity ratio of 0.33. Alexion Pharmaceuticals has a 52 week low of $120.20 and a 52 week high of $121.73.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.18. The business had revenue of $930.90 million during the quarter, compared to the consensus estimate of $920.50 million. Alexion Pharmaceuticals had a return on equity of 13.70% and a net margin of 14.46%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.38 earnings per share. research analysts anticipate that Alexion Pharmaceuticals will post 6.28 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on ALXN. Deutsche Bank set a $161.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. Credit Suisse Group reissued an “outperform” rating and issued a $149.00 price target (up from $147.00) on shares of Alexion Pharmaceuticals in a report on Friday, March 16th. Robert W. Baird set a $160.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, March 15th. Nomura boosted their price target on Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a report on Thursday, March 15th. Finally, BidaskClub raised Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, March 17th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twenty have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $155.50.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply